Grufity logoGrufity logo
StocksFundsSearch Filings

BioLife Solutions Inc Stock Research

BLFS

23.36USD+0.86(+3.82%)Market Closed

Market Summary

USD23.36+0.86
Market Closed
3.82%

BLFS Alerts

BLFS Stock Price

BLFS RSI Chart

BLFS Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-6.9

Price/Sales (Trailing)

6.19

EV/EBITDA

-6.94

Price/Free Cashflow

-65.24

BLFS Price/Sales (Trailing)

BLFS Profitability

EBT Margin

-72.07%

Return on Equity

-25.49%

Return on Assets

-21.34%

Free Cashflow Yield

-1.53%

BLFS Fundamentals

BLFS Revenue

Revenue (TTM)

163.2M

Revenue Y/Y

4.09%

Revenue Q/Q

-14.81%

BLFS Earnings

Earnings (TTM)

-146.5M

Earnings Y/Y

-94.08%

Earnings Q/Q

72.7%

Price Action

52 Week Range

12.6026.96
(Low)(High)

Last 7 days

4.9%

Last 30 days

33.0%

Last 90 days

2.5%

Trailing 12 Months

58.6%

BLFS Financial Health

Current Ratio

3.68

Debt/Equity

0.06

Debt/Cashflow

-0.65

BLFS Investor Care

Shares Dilution (1Y)

2.27%

Diluted EPS (TTM)

-3.29

Peers (Alternatives to BioLife Solutions)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
109.8B
30.8B
-9.29% -16.09%
26.95
3.57
-3.19% -17.32%
107.6B
6.4B
1.94% 34.00%
82.01
16.73
8.89% -20.19%
49.3B
5.5B
-7.47% -19.49%
33.14
8.97
2.68% -3.23%
21.8B
3.7B
-12.40% 0.13%
69.2
5.89
-8.10% -55.37%
19.5B
4.1B
-8.55% 1.55%
25.84
4.8
-24.76% -51.48%
MID-CAP
11.8B
884.6M
9.37% 108.01%
1.8K
13.39
13.08% 200.12%
5.4B
2.6B
-14.32% -23.28%
25.47
2.1
1.47% -29.43%
3.6B
1.1B
-5.65% 2.15%
-38.56
3.29
7.68% -238.55%
2.4B
1.0B
-8.50% -35.10%
-28.78
2.25
1.66% 19.79%
2.4B
119.1M
-8.56% 141.99%
-83.21
19.75
204.77% 39.65%
SMALL-CAP
1.6B
169.8M
-7.71% 2.34%
-19.37
9.27
25.95% -102.42%
1.1B
814.3M
-18.92% -16.55%
25.06
1.37
6.96% 121.89%
1.0B
163.2M
33.03% 58.59%
-6.9
6.19
17.84% -885.82%
255.0M
369.0M
-17.13% -57.43%
-2.84
0.69
5.00% -353.73%
54.4M
438.9M
-7.48% -74.66%
-0.63
0.12
-25.59% -12.50%

Financials for BioLife Solutions

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue0.9%163,242,000161,759,000154,805,000147,858,000138,529,000
  S&GA Expenses7.3%23,150,00021,570,00020,361,00019,149,00016,876,000
  R&D Expenses2.5%15,169,00014,798,00014,205,00013,999,00013,616,000
EBITDA-4.9%-104,198,000-99,319,000-28,579,000--
EBITDA Margin-0.2%-0.67-0.67-0.21--
Earnings Before Taxes-4.1%-150,784,000-144,827,000-112,837,000-107,190,000-35,573,000
EBT Margin-0.6%-0.72-0.72-0.25--
Interest Expenses69.3%992,000586,000682,000573,000543,000
Net Income-4.8%-146,453,000-139,805,000-105,322,000-95,286,000-14,856,000
Net Income Margin-5.7%-0.67-0.64-0.10--
Free Cahsflow-2.6%-24,622,000-24,001,000-22,458,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-0.8%446450488470544
  Current Assets-4.1%133138136118119
    Cash Equivalents-1.7%19.0019.0027.0024.0059.00
  Inventory18.4%41.0035.0034.0033.0030.00
  Net PPE10.4%26.0024.0022.0019.0018.00
  Goodwill0%225225225225225
Liabilities2.7%88.0086.0079.0058.0065.00
  Current Liabilities6.1%47.0045.0037.0033.0035.00
  Long Term Debt248.0%26.008.007.00--
    LT Debt, Current-31.1%1.002.002.001.001.00
    LT Debt, Non Current-0.4%24.0024.0024.006.006.00
Shareholder's Equity-1.7%358364408412479
  Retained Earnings-5.6%-260-246-194-184-112
  Additional Paid-In Capital1.2%619612604598591
Shares Outstanding1.1%43.0043.0043.0043.0042.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations61.4%-3.28-8.49-17.12-16.53-14.34
  Share Based Compensation7.8%27.0025.0023.0021.0018.00
Cashflow From Investing8.9%-52.92-58.12-45.76-31.89-11.03
Cashflow From Financing-2.3%16.0016.0015.00-3.63-4.17

Risks for BLFS

What is the probability of a big loss on BLFS?

97.7%


Probability that BioLife Solutions stock will be more than 20% underwater in next one year

86.2%


Probability that BioLife Solutions stock will be more than 30% underwater in next one year.

63.1%


Probability that BioLife Solutions stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BLFS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BioLife Solutions was unfortunately bought at previous high price.

Drawdowns

Returns for BLFS

Cumulative Returns on BLFS

16.6%


10-Year Cumulative Returns

47%


7-Year Cumulative Returns

16.9%


5-Year Cumulative Returns

12.4%


3-Year Cumulative Returns

What are the long-term rolling returns for BLFS?

FIve years rolling returns for BioLife Solutions.

Annualized Returns

Which funds bought or sold BLFS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-14.7
397,895
20,968,900
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
2.55
1,451,000
7,884,000
0.01%
2023-05-18
JPMORGAN CHASE & CO
added
0.31
1,462,000
8,815,000
-%
2023-05-17
Thrivent Financial for Lutherans
added
2.11
1,375,000
7,614,000
0.02%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
358,658
358,658
-%
2023-05-16
Meros Investment Management, LP
added
4.00
955,704
4,888,700
2.78%
2023-05-16
FRED ALGER MANAGEMENT, LLC
reduced
-2.66
5,875,300
41,873,400
0.22%
2023-05-16
Baker Avenue Asset Management, LP
unchanged
-
3,578
21,924
-%
2023-05-16
Rockefeller Capital Management L.P.
sold off
-100
-90,000
-
-%
2023-05-15
KENFARB & CO.
unchanged
-
17,800
108,750
0.10%

1–10 of 45

Latest Funds Activity

Are funds buying BLFS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BLFS
No. of Funds

BioLife Solutions News

Defense World
Swiss National Bank Boosts Stock Holdings in BioLife Solutions, Inc ....
Defense World,
46 hours ago
GuruFocus.com
EVP & Chief Scientific Officer.
GuruFocus.com,
3 days ago

Schedule 13G FIlings of BioLife Solutions

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
5.77%
2,466,931
SC 13G/A
Jan 26, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 20, 2023
blackrock inc.
12.8%
5,477,126
SC 13G/A
Jan 11, 2023
millennium management llc
1.6%
670,202
SC 13G/A
Jul 08, 2022
blackrock inc.
11.5%
4,893,203
SC 13G
Jun 22, 2022
millennium management llc
5.1%
2,166,344
SC 13G
Feb 09, 2022
vanguard group inc
5.16%
2,147,258
SC 13G
Feb 01, 2022
blackrock inc.
8.8%
3,655,057
SC 13G/A
Nov 01, 2021
villiger walter
4.86%
1,979,226
SC 13D/A
Sep 09, 2021
blackrock inc.
11.1%
4,528,723
SC 13G

BLFS Fair Value

Show Fair-Value

Recent SEC filings of BioLife Solutions

View All Filings
Date Filed Form Type Document
May 25, 2023
4
Insider Trading
May 23, 2023
4
Insider Trading
May 19, 2023
4/A
Insider Trading
May 19, 2023
8-K
Current Report
May 18, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading
May 17, 2023
4
Insider Trading

Latest Insider Trading transactions for BLFS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-25
Mathew Aby J.
acquired
20,600
2.06
10,000
evp & chief scientific officer
2023-05-25
Mathew Aby J.
sold
-223,300
22.33
-10,000
evp & chief scientific officer
2023-05-24
Mathew Aby J.
acquired
20,600
2.06
10,000
evp & chief scientific officer
2023-05-24
Mathew Aby J.
sold
-221,400
22.14
-10,000
evp & chief scientific officer
2023-05-22
Casdin Partners Master Fund, L.P.
bought
545,790
21.8552
24,973
-
2023-05-19
Casdin Partners Master Fund, L.P.
bought
1,127,430
22.5486
50,000
-
2023-05-18
Casdin Partners Master Fund, L.P.
bought
652,692
21.7564
30,000
-
2023-05-17
Rice Michael
sold
-701,326
21.04
-33,333
ceo
2023-05-17
Casdin Partners Master Fund, L.P.
bought
639,446
21.2957
30,027
-
2023-05-16
Wichterman Troy
sold
-2,659
19.41
-137
chief financial officer

1–10 of 50

Michael P. Rice
440
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Income Statement

2023-03-31
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue$ 37,703$ 36,220
Costs and operating expenses:  
General and administrative14,84211,530
Sales and marketing6,4714,891
Research and development4,1523,781
Intangible asset amortization1,4592,863
Acquisition costs011
Change in fair value of contingent consideration720(3,335)
Total operating expenses51,30844,187
Operating loss(13,605)(7,967)
Other expense:  
Interest expense, net(411)(184)
Other income394131
Total other expense, net(17)(53)
Loss before income tax (expense) benefit(13,622)(8,020)
Income tax (expense) benefit(92)599
Net loss(13,714)(7,421)
Net loss attributable to common shareholders:  
Basic and Diluted$ (13,714)$ (7,421)
Basic and Diluted (in dollars per share)$ (0.32)$ (0.18)
Weighted average shares used to compute loss per share attributable to common shareholders:  
Basic and Diluted (in shares)43,027,61242,014,055
Product [Member]  
Revenue$ 31,593$ 30,388
Costs and operating expenses:  
Cost of goods and services18,39720,384
Service Revenue [Member]  
Revenue4,4713,090
Costs and operating expenses:  
Cost of goods and services3,8912,145
Rental Revenue [Member]  
Revenue1,6392,742
Costs and operating expenses:  
Cost of goods and services$ 1,376$ 1,917

BLFS Balance Sheet

2023-03-31
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 19,105$ 19,442
Restricted cash3131
Available-for-sale securities, current portion35,78043,260
Accounts receivable, trade, net of allowance for doubtful accounts of $956 and $739 as of March 31, 2023 and December 31, 2022, respectively30,34333,936
Inventories41,32934,904
Prepaid expenses and other current assets6,2016,879
Total current assets132,789138,452
Assets held for rent, net9,0059,064
Property and equipment, net26,10023,638
Operating lease right-of-use assets, net15,59215,292
Financing lease right-of-use assets, net242272
Long-term deposits and other assets284281
Available-for-sale securities, long-term2,0191,332
Equity investments5,0695,069
Total intangible assets, net30,62932,088
Goodwill224,741224,741
Total assets446,470450,229
Current liabilities:  
Accounts payable15,52515,367
Accrued expenses and other current liabilities10,7019,782
Sales taxes payable4,5854,151
Warranty liability8,8958,312
Lease liabilities, operating, current portion2,9062,860
Lease liabilities, financing, current portion161158
Debt, current portion1,2501,814
Contingent consideration, current portion3,2962,138
Total current liabilities47,31944,582
Contingent consideration, long-term1,8802,318
Lease liabilities, operating, long-term15,11414,962
Lease liabilities, financing, long-term95126
Debt, long-term23,69223,793
Deferred tax liabilities263250
Other long-term liabilities010
Total liabilities88,36386,041
Commitments and contingencies (Note 12)
Shareholders’ equity:  
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2023 and December 31, 202200
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,289,969 and 42,832,231 shares issued and outstanding, respectively, as of March 31, 2023 and December 31, 20224343
Additional paid-in capital619,227611,739
Accumulated other comprehensive loss, net of taxes(534)(679)
Accumulated deficit(260,629)(246,915)
Total shareholders’ equity358,107364,188
Total liabilities and shareholders’ equity$ 446,470$ 450,229